Booya. We’re up 143% With Ardelyx (ARDX) in Three Months – and That Ain’t...
Ardelyx Adds 16% to $3.82 as Wedbush Upgrades After Q4 Earnings.
Ardelyx ( NASDAQ: ARDX ) gained 35% Friday after the biotech reported better-than-expected financials...
We Warned About VERU (VERU) $2.50, Down 89%.
Down 35% Today, and 89% from $24, and a $1.9 Billion Market Cap, Only 7 Months ago.
The FDA says we have some nice parting...
Silo Pharma (SILO) $2.25, Now Our Favorite Psychedelic.
We Liked it at $3.50, we Love it at $2.25.
Down but not out. Now trading below the cash they have in the bank, this...
SILO Pharma (SILO) Gains 53%
For Now, Volatility Remains and the Traders, Seem to be Having the Most Fun.
Silo Pharma Gains 53% Intraday on Patent (Ketamine) Related News
Our opinion...
Citius Pharma (CTXR). Reports Fiscal First Quarter 2023 Financial Results and Provides Business Update
$36.9 million in cash and cash equivalents as of December 31, 2022 ; runway through February 2024
Uptick in patient recruitment for Mino-Lok® Phase 3 trial
Halo-Lido Phase 2b trial nearing completion
CRANFORD,...
Silo Pharma (SILO) $2.67 Announces $1 Million Stock Buyback.
Yes it doesn't sound like a lot of money on the surface. But the stock is so grossly undervalued (in our opinion) and there...
Doubling Down After ATAI’s (ATAI) Anti Depression Treatment Bombs in Front of FDA.
Both a bad day and a Good day for Psychedelics. The Psychedelic Sector Holds Firm.
Atai was founded in 2018 and went public in June...
Ouch, for Now. Progressive Care Does 200:1 Reverse.
MASSIVE REVERSE SPLIT
Let's just watch from the sidelines for now. If you had 100,000 shares last Friday, you now own 500 shares. Opened at...
He Shoots And He Scores. Ardelyx (ARDX) Gains 78%. Happy New Year!
Ah yes, and Gains Come to the Patient, as the FDA Moves the Ardelyx Ball Further Along.
Despite the 78% gain since November 17th, the...
Silo Pharma (SILO) Announces Positive Study Results of SPU- 21 for Arthritis
SPU-21 effective in controlling arthritis progression.
SPU-21 Demonstrates Positive Data in Arthritis Suppression using Silo’s Novel Joint Homing Peptide
ENGLEWOOD CLIFFS, NJ, Dec. 30, 2022 (GLOBE...
Latest article
Jeffrey Gundlach: Reckoning is Coming.
Jeffrey Edward Gundlach is a businessman, fund manager, and philanthropist. He is the founder of DoubleLine Capital, an investment firm.
On 11 November 2020, Gundlach remarked in an interview with...
Who’s the Next Eric Sprott?
To say Eric Sprott has left a legendary mark on the world of mining investment would be an understatement. With a career spanning five...
Perpetua (PPTA) Raises $300 Million.
Not a bad day in Idaho. $300 million banked! We look at the dip as a buying opportunity, as does John Paulson & Co.,...
